Search Results for: MSD
Special ESG
A Close Look at the Evolution of ESG in Biopharma
2023-05-22
M&A MerckAutoimmune Disease
Merck Buys Prometheus For $10.8 Billion, Lands Promising Autoimmune Asset
2023-04-17
BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)
2023-03-27
Licensing Antibody Therapy
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
Trials & Approvals Keytruda
Merck’s Keytruda Falls Short In Two Trials
2023-03-01
Deals Oncology
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
2023-02-07
Trials & Approvals IgA Nephropathy
Vera Therapeutics Eyes Phase 3 For Kidney Disease Candidate Following Positive Data
2023-01-04
Special FDA Approval
GeneOnline’s Pick: Top 10 New FDA-approved Drugs in 2022
2022-12-30
China Keytruda
Antengene To Pair CD73 Inhibitor With Merck’s Keytruda In Clinical Collaboration
2022-12-27
M&A Merck
Merck Expands Hematology Portfolio With $1.35 Billion Imago Buy
2022-11-22
Partnerships Ginkgo Bioworks
Ginkgo Bioworks and Merck’s Collaboration Worth Up to $144 million
2022-10-13
Partnerships Keytruda
Moderna Gets $250 Million from MSD in Personal Cancer Vaccine Licensing Option
2022-10-12
Trials & Approvals AstraZeneca
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Trials & Approvals Breast Cancer
AstraZeneca and Merck’s HER2-negative Breast Cancer Treatment Wins Yet Another Approval
2022-08-25
PRNewswire
Everest Medicines Announces Interim Results for First Half of 2022
2022-08-24
1 2 3 4 5
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top